Suchergebnisse

Reseña del libro Carlota de Bélgica. Emperatriz de México

Cultured neurons obtained from a hypomorphous MAP1B mutant mouse line display a selective and significant inhibition of axon formation that reflects a delay in axon outgrowth and a reduced rate of elongation. This phenomenon is paralleled by decreased microtubule formation and dynamics, which is dramatic at the distal axonal segment, as well as in growth cones, where the more recently assembled microtubule polymer normally predominates. These neurons also have aberrant growth cone formation and increased actin-based protrusive activity. Taken together, this study provides direct evidence showing that by promoting microtubule dynamics and regulating cytoskeletal organization MAP1B has a crucial role in axon formation. ; This work was supported by grants from the Spanish Direccion General de Investigacion Cientifica y Tecnica, Comunidad de Madrid, European Union, and an institutional grant from Formation de Recherche Associee to J.A. It was also supported by grants from Consejo Nacional de Investigaciones Cientificas y Tecnicas de Argentina (PICT-PIP 4906), FONCyT (PICT 05-00000-00937 and 99-5-6179), CONICOR, and a Howard Hughes Medical Institute Grant (HMMI 75197-553201) awarded under the International Research Scholars Program to A.C. An A.E.C.I./I.C.I. predoctoral fellowship was awarded to C.G.-B. The MAP1B mutant mouse was generated with financial support from Amgen and the Max Planck Society in the laboratory of Prof. P. Gruss. ; Peer reviewed

[EN] Zero-energy Andreev levels in hybrid semiconductor-superconductor nanowires mimic all expected Majorana phenomenology, including 2 e∕ h conductance quantisation, even where band topology predicts trivial phases. This surprising fact has been used to challenge the interpretation of various transport experiments in terms of Majorana zero modes. Here we show that the Andreev versus Majorana controversy is clarified when framed in the language of non-Hermitian topology, the natural description for quantum systems open to the environment. This change of paradigm allows one to understand topological transitions and the emergence of zero modes in more general systems than can be described by band topology. This is achieved by studying exceptional point bifurcations in the complex spectrum of the system's non-Hermitian Hamiltonian. Within this broader topological classification, Majoranas from both conventional band topology and a large subset of Andreev levels at zero energy are in fact topologically equivalent, which explains why they cannot be distinguished. ; Research supported by the Spanish Ministry of Science, Innovation and Universities through Grants PGC2018-097018-B-I00, FIS2015-65706-P, FIS2015-64654-P, FIS2016-80434-P (AEI/FEDER, EU), the FPI programme BES-2016-078122, the Ramón y Cajal programme Grants RYC-2011-09345, RYC-2013-14645, the María de Maeztu Programme for Units of Excellence in R&D (MDM-2014-0377), and the European Union's Horizon 2020 research and innovation programme under the FETOPEN Grant Agreement No. 828948. We also acknowledge support from CSIC Research Platform on Quantum Technologies PTI-001.

In this article, Serrano, Ávila and colleagues show that cyclic expression of Yamanaka factors Oct4, Sox2, Klf4, and c-Myc in the hippocampus prevent the age-dependent reduction in the epigenetic marker H3K9 trimethylation (H3K9me3) and alter adult hippocampal neurogenesis. These cellular changes were accompanied by an improvement in mouse performance in the object recognition test.Post-translational epigenetic modifications take place in mouse neurons of the dentate gyrus (DG) with age. Here, we report that age-dependent reduction in H3K9 trimethylation (H3K9me3) is prevented by cyclic induction of the Yamanaka factors used for cell reprogramming. Interestingly, Yamanaka factors elevated the levels of migrating cells containing the neurogenic markers doublecortin and calretinin, and the levels of the NMDA receptor subunit GluN2B. These changes could result in an increase in the survival of newborn DG neurons during their maturation and higher synaptic plasticity in mature neurons. Importantly, these cellular changes were accompanied by an improvement in mouse performance in the object recognition test over long time. We conclude that transient cyclic reprogramming in vivo in the central nervous system could be an effective strategy to ameliorate aging of the central nervous system and neurodegenerative diseases. ; Spanish Ministry of Economy and Competitiveness (PGC-2018-09177-B-100) and Centro de Investigacio´n Biome´dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, ISCIII). Spanish Ministry of Economy and Competitiveness (BFU2016-77885-P) and Comunidad de Madrid co-financed with the Structural Funds of the European Union (S2017/BMD-3700 (NEUROMETAB-CM)). Work in the laboratory of M.S. was funded by the IRB and by grants from the MINECO co-funded by the European Regional Development Fund (SAF2017-82613-R), the European Research Council (ERC-2014-AdG/669622), and ''La Caixa'' Foundation. An institutional grant from the Fundación Ramón Areces to the CBMSO

La participación social se ha promovido decididamente en políticas públicas latinoamericanas de renombre como el Programa Nacional Solidaridad, Progresa, Oportunidades, la Cruzada Nacional contra el Hambre (México), Hambre Cero y el Plan Brasil Sin Miseria (Brasil), así como las políticas de seguridad alimentaria de Cuba y Uruguay. Ahora, en México, con la política Seguridad Alimentaria Mexicana se busca impulsar al sector agropecuario para aumentar la producción, el beneficio económico y el bienestar de las comunidades rurales con la participación de productores y sus organizaciones. Por ello, se realizó un análisis hermenéutico de enfoque sociocrítico sobre las políticas alimentarias incluyentes con mayor éxito relativo en Latinoamérica con objeto de contrastarlas con el componente de la participación social considerado en la política de Seguridad Alimentaria Mexicana. Se encontró que las políticas alimentarias con mayor éxito relativo muestran una mayor participación de los productores y sus organizaciones; no obstante, hay poca evidencia empírica de la política social que interviene en las políticas públicas, lo que limita su análisis en función de resultados.

It is well known that transgenic mice overexpressing human tau protein with P301S mutation driven by the mouse prion protein promoter show clasping and limb retraction, hunched back and paralysis, followed by inability to feed that results in death around 12 months of age. To understand these motor deficits, we have carried out rotarod tests on PS19 line and demonstrated how they worsened during aging. Then, we have analyzed if these phenotypic characteristics correlate with sciatic nerve degeneration. We first demonstrated by western blot and immunohistochemistry that the sciatic nerve expresses the transgenic tau protein; then, electron microscopy studies showed alterations in myelin, mainly a detachment of myelin lamellae at Schmidt-Lanterman clefts. Similar motor deficits and myelin alterations have been previously reported in tau knockout and overexpressing transgenic mice; taking into account that PS19 model is widely used to study tauopathies, we suggest that analyzing the expression of transgenic tau protein and myelin abnormalities in the sciatic nerve should be considered when studying some features as motor performance or survival. ; Spanish Ministry of Economy and Competitiveness (BFU2016-77885-P), Comunidad de Madrid cofinanced with the Structural Funds of the European Union (S2017/BMD-3700 (NEUROMETAB-CM)), Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, ISCIII), and from an institutional grant from the Fundación R. Areces

Prolonged seizures (status epilepticus, SE) may drive hippocampal dysfunction and epileptogenesis, at least partly, through an elevation in neurogenesis, dysregulation of migration and aberrant dendritic arborization of newly-formed neurons. MicroRNA-22 was recently found to protect against the development of epileptic foci, but the mechanisms remain incompletely understood. Here, we investigated the contribution of microRNA-22 to SE-induced aberrant adult neurogenesis. SE was induced by intraamygdala microinjection of kainic acid (KA) to model unilateral hippocampal neuropathology in mice. MicroRNA-22 expression was suppressed using specific oligonucleotide inhibitors (antagomir-22) and newly-formed neurons were visualized using the thymidine analog iodo-deoxyuridine (IdU) and a green fluorescent protein (GFP)-expressing retrovirus to visualize the dendritic tree and synaptic spines. Using this approach, we quantified differences in the rate of neurogenesis and migration, the structure of the apical dendritic tree and density and morphology of dendritic spines in newly-formed neurons.SE resulted in an increased rate of hippocampal neurogenesis, including within the undamaged contralateral dentate gyrus (DG). Newly-formed neurons underwent aberrant migration, both within the granule cell layer and into ectopic sites. Inhibition of microRNA-22 exacerbated these changes. The dendritic diameter and the density and average volume of dendritic spines were unaffected by SE, but these parameters were all elevated in mice in which microRNA-22 was suppressed. MicroRNA-22 inhibition also reduced the length and complexity of the dendritic tree, independently of SE. These data indicate that microRNA-22 is an important regulator of morphogenesis of newly-formed neurons in adults and plays a role in supressing aberrant neurogenesis associated with SE. ; Science Foundation Ireland (13/SIRG/2098, 17/CDA/4708 and 16/TIDA/4059 to TE, 13/SIRG/2114 to EJ-M, 17/TIDA/5002 to CR, 13/IA/1891 and 16/RC/3948 to DH and co-funded under the European Regional Development Fund and by FutureNeuro Industry partners) from the Health Research Board (HRA-POR-2015-1243 to TE); European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement n 602130 (to DH), from the H2020 Marie Skłowdowksa-Curie Actions Individual Fellowship (753527 to EB), from the European Union's Horizon 2020; Comunidad de Madrid to MM-P, from Fundación ''La Caixa'' to JM-R and from Areces Foundation C-XVIII and the Minister of Science and Universities of Spain BFU2014-53654-P to MM-P ; Peer Reviewed

Tau hyperphosphorylation can be considered as one of the hallmarks of Alzheimer's disease and other tauophaties. Besides its well-known role as a microtubule associated protein, Tau displays a key function as a protector of genomic integrity in stress situations. Phosphorylation has been proven to regulate multiple processes including nuclear translocation of Tau. In this contribution, we are addressing the physicochemical nature of DNA-Tau interaction including the plausible influence of phosphorylation. By means of surface plasmon resonance (SPR) we measured the equilibrium constant and the free energy, enthalpy and entropy changes associated to the Tau-DNA complex formation. Our results show that unphosphorylated Tau binding to DNA is reversible. This fact is in agreement with the protective role attributed to nuclear Tau, which stops binding to DNA once the insult is over. According to our thermodynamic data, oscillations in the concentration of dephosphorylated Tau available to DNA must be the variable determining the extent of Tau binding and DNA protection. In addition, thermodynamics of the interaction suggest that hydrophobicity must represent an important contribution to the stability of the Tau-DNA complex. SPR results together with those from Tau expression in HEK cells show that phosphorylation induces changes in Tau protein which prevent it from binding to DNA. The phosphorylation-dependent regulation of DNA binding is analogous to the Tau-microtubules binding inhibition induced by phosphorylation. Our results suggest that hydrophobicity may control Tau location and DNA interaction and that impairment of this Tau-DNA interaction, due to Tau hyperphosphorylation, could contribute to Alzheimer's pathogenesis. © 2014 Camero et al. ; Spanish Government and Comunidad de Madrid. CIBERNED (Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas ; Peer Reviewed

Tau protein has been proposed as a trigger of Alzheimer's disease once it is hyperphosphorylated. However, the role that native tau forms play inside the neuronal nucleus remains unclear. In this work we present results concerning the interaction of tau protein with double-stranded DNA, single-stranded DNA, and also with a histone-DNA complex. The tau-DNA interaction results in a structure resembling the beads-on-a-string form produced by the binding of histone to DNA. DNA retardation assays show that tau and histone induce similar DNA retardation. A surface plasmon resonance study of tau-DNA interaction also confirms the minor groove of DNA as a binding site for tau, similarly to the histone binding. A residual binding of tau to DNA in the presence of Distamycin A, a minor groove binder, suggests the possibility that additional structural domains on DNA may be involved in tau interaction. Finally, DNA melting experiments show that, according to the Zipper model of helix-coil transition, the binding of tau increases the possibility of opening the DNA double helix in isolated points along the chain, upon increasing temperature. This behavior is analogous to histones and supports the previously reported idea that tau could play a protective role in stress situations. Taken together, these results show a similar behavior of tau and histone concerning DNA binding, suggesting that post-translational modifications on tau might impair the role that, by modulating the DNA function, might be attributable to the DNA-tau interaction. © 2014-IOS Press and the authors. All rights reserved. ; Spanish Government (SAF2006-02424 and SAF2010-15525) and Comunidad de Madrid (P2009/TIC-1476).

This paper shows the acoustic emission (AE) analysis recorded during the loading process of reinforced concrete (RC) structures subjected to bidirectional seismic loadings. Two waffle plates (bidirectional) supported by isolated square columns were tested on a shaking table with a progressive and increasing ground acceleration until the final collapse. Each specimen was subjected to a different loading history. A relevant delay in the beginning of the significant AE energy is observed as the peak value of the ground acceleration increases. Based on this result, a new AE temporal damage index (TDI), defined as the time difference between the onset of the significant AE activity and the onset of the loading that causes this AE activity, is proposed and validated by comparing it with the plastic strain energy released by the concrete, typically used as a reliable damage level indicator. Good agreement was observed for both specimens and seismic inputs. ; This research was supported by the regional government of Andalucía, Consejería de Innovación, Ciencia y Tecnología, Project TEP-02429, by the Spanish Ministry of Economy and Competitivity, research project reference MEC BIA2017 88814 R and received funds from the European Union (Fonds Européen de Dévelopment Régional).

Glycogen synthase kinase-3 (GSK-3) is ubiquitously expressed throughout the brain and involved in vital molecular pathways such as cell survival and synaptic reorganization and has emerged as a potential drug target for brain diseases. A causal role for GSK-3, in particular the brain-enriched GSK-3ß isoform, has been demonstrated in neurodegenerative diseases such as Alzheimer's and Huntington's, and in psychiatric diseases. Recent studies have also linked GSK-3 dysregulation to neuropathological outcomes in epilepsy. To date, however, there has been no genetic evidence for the involvement of GSK-3 in seizure-induced pathology. Status epilepticus (prolonged, damaging seizure) was induced via a microinjection of kainic acid into the amygdala of mice. Studies were conducted using two transgenic mouse lines: a neuron-specific GSK-3ß overexpression and a neuron-specific dominant-negative GSK-3ß (GSK-3ß-DN) expression in order to determine the effects of increased or decreased GSK-3ß activity, respectively, on seizures and attendant pathological changes in the hippocampus. GSK-3 inhibitors were also employed to support the genetic approach. Status epilepticus resulted in a spatiotemporal regulation of GSK-3 expression and activity in the hippocampus, with decreased GSK-3 activity evident in non-damaged hippocampal areas. Consistent with this, overexpression of GSK-3ß exacerbated status epilepticus-induced neurodegeneration in mice. Surprisingly, decreasing GSK-3 activity, either via overexpression of GSK-3ß-DN or through the use of specific GSK-3 inhibitors, also exacerbated hippocampal damage and increased seizure severity during status epilepticus. In conclusion, our results demonstrate that the brain has limited tolerance for modulation of GSK-3 activity in the setting of epileptic brain injury. These findings caution against targeting GSK-3 as a treatment strategy for epilepsy or other neurologic disorders where neuronal hyperexcitability is an underlying pathomechanism. ; Marie Curie International Mobility Fellowship, the Health Research Board (PD/2009/31 to T.E. and HRA_POR/2011/41 to D.C.H.); Science Foundation Ireland (13/SIRG/2098 and 17/CDA/4708 to T.E. and 16/RC/3948 to D.C.H.) and co-funded under the European Regional Development Fund and by FutureNeuro industry partners;); from the H2020 Marie Skłowdowksa-Curie Actions Individual Fellowship (753527 to E.B.); from the European Union's Horizon 2020 research and innovation programme under the Marie Sklowdowska-Cuire grant agreement (No. 766124 to T.E.); grants from Ministerio de Economía Industria y Competitividad of Spain SAF2009-08233 and SAF2015-65371-R to J.J.L., SAF2016-78603-R to M.M. and BFU2016-77885-P to F.H.; grant PI2015-2/06-3 from CIBERNED-ISCIII to J.J.L.; and institutional grants to CBMSO from Fundación Ramón Areces and Fundación Banco de Santander ; Peer Reviewed

14 p.-5 fig. ; Glycogen synthase kinase-3 (GSK-3) is ubiquitously expressed throughout the brain and involved in vital molecular pathways such as cell survival and synaptic reorganization and has emerged as a potential drug target for brain diseases. A causal role for GSK-3, in particular the brain-enriched GSK-3β isoform, has been demonstrated in neurodegenerative diseases such as Alzheimer's and Huntington's, and in psychiatric diseases. Recent studies have also linked GSK-3 dysregulation to neuropathological outcomes in epilepsy. To date, however, there has been no genetic evidence for the involvement of GSK-3 in seizure-induced pathology. Status epilepticus (prolonged, damaging seizure) was induced via a microinjection of kainic acid into the amygdala of mice. Studies were conducted using two transgenic mouse lines: a neuron-specific GSK-3β overexpression and a neuron-specific dominant-negative GSK-3β (GSK-3β-DN) expression in order to determine the effects of increased or decreased GSK-3β activity, respectively, on seizures and attendant pathological changes in the hippocampus. GSK-3 inhibitors were also employed to support the genetic approach. Status epilepticus resulted in a spatiotemporal regulation of GSK-3 expression and activity in the hippocampus, with decreased GSK-3 activity evident in non-damaged hippocampal areas. Consistent with this, overexpression of GSK-3β exacerbated status epilepticus-induced neurodegeneration in mice. Surprisingly, decreasing GSK-3 activity, either via overexpression of GSK-3β-DN or through the use of specific GSK-3 inhibitors, also exacerbated hippocampal damage and increased seizure severity during status epilepticus. In conclusion, our results demonstrate that the brain has limited tolerance for modulation of GSK-3 activity in the setting of epileptic brain injury. These findings caution against targeting GSK-3 as a treatment strategy for epilepsy or other neurologic disorders where neuronal hyperexcitability is an underlying pathomechanism. ; This work was supported by funding from the Sixth Framework Programme (MIRG-CT-2004-014567, to D.C.H.) a IRCSET-Marie Curie International Mobility Fellowship, the Health Research Board (PD/2009/31 to T.E. and HRA_POR/ 2011/41 to D.C.H.); Science Foundation Ireland (13/SIRG/2098 and 17/CDA/ 4708 to T.E. and 16/RC/3948 to D.C.H.) and co-funded under the European Regional Development Fund and by FutureNeuro industry partners;); from the H2020 Marie Skłowdowksa-Curie Actions Individual Fellowship (753527 to E.B.); from the European Union's Horizon 2020 research and innovation programme under the Marie Sklowdowska-Cuire grant agreement (No. 766124 to T.E.); grants from Ministerio de Economía Industria y Competitividad of Spain SAF2009-08233 and SAF2015-65371-R to J.J.L., SAF2016-78603-R to M.M. and BFU2016-77885-P to F.H.; grant PI2015-2/06-3 from CIBERNED-ISCIII to J.J.L.; and institutional grants to CBMSO from Fundación Ramón Areces and Fundación Banco de Santander. ; Peer reviewed

CurePSP Foundation, the Peebler PSP Research Foundation, and National Institutes on Health (NIH) grants R37 AG 11762, R01 PAS-03-092, P50 NS72187, P01 AG17216 [National Institute on Aging(NIA)/NIH], MH057881 and MH077930 [National Institute of Mental Health (NIMH)]. Work was also supported in part by the NIA Intramural Research Program, the German National Genome Research Network (01GS08136-4) and the Deutsche Forschungsgemeinschaft (HO 2402/6-1), Prinses Beatrix Fonds (JCvS, 01–0128), the Reta Lila Weston Trust and the UK Medical Research Council (RdS: G0501560). The Newcastle Brain Tissue Resource provided tissue and is funded in part by a grant from the UK Medical Research Council (G0400074), by the Newcastle NIHR Biomedical Research Centre in Ageing and Age Related Diseases to the Newcastle upon Tyne Hospitals NHS Foundation Trust, and by a grant from the Alzheimer's Society and Alzheimer's Research Trust as part of the Brains for Dementia Resarch Project. We acknowledge the contribution of many tissue samples from the Harvard Brain Tissue Resource Center. We also acknowledge the 'Human Genetic Bank of Patients affected by Parkinson Disease and parkinsonism' (http://www.parkinson.it/dnabank.html) of the Telethon Genetic Biobank Network, supported by TELETHON Italy (project n. GTB07001) and by Fondazione Grigioni per il Morbo di Parkinson. The University of Toronto sample collection was supported by grants from Wellcome Trust, Howard Hughes Medical Institute, and the Canadian Institute of Health Research. Brain-Net-Germany is supported by BMBF (01GI0505). RdS, AJL and JAH are funded by the Reta Lila Weston Trust and the PSP (Europe) Association. RdS is funded by the UK Medical Research Council (Grant G0501560) and Cure PSP+. ZKW is partially supported by the NIH/NINDS 1RC2NS070276, NS057567, P50NS072187, Mayo Clinic Florida (MCF)Research Committee CR programs (MCF #90052030 and MCF #90052030), and the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch (MCF #90052031/PAU #90052). The Mayo Clinic College of Medicine would like to acknowledge Matt Baker, Richard Crook, Mariely DeJesus-Hernandez and Nicola Rutherford for their preparation of samples. PP was supported by a grant from the Government of Navarra ("Ayudas para la Realización de Proyectos de Investigación" 2006–2007) and acknowledges the "Iberian Atypical Parkinsonism Study Group Researchers", i.e. Maria A. Pastor, Maria R. Luquin, Mario Riverol, Jose A. Obeso and Maria C Rodriguez-Oroz (Department of Neurology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain), Marta Blazquez (Neurology Department, Hospital Universitario Central de Asturias, Oviedo, Spain), Adolfo Lopez de Munain, Begoña Indakoetxea, Javier Olaskoaga, Javier Ruiz, José Félix Martí Massó (Servicio de Neurología, Hospital Donostia, San Sebastián, Spain), Victoria Alvarez (Genetics Department, Hospital Universitario Central de Asturias, Oviedo, Spain), Teresa Tuñon (Banco de Tejidos Neurologicos, CIBERNED, Hospital de Navarra, Navarra, Spain), Fermin Moreno (Servicio de Neurología, Hospital Ntra. Sra. de la Antigua, Zumarraga, Gipuzkoa, Spain), Ainhoa Alzualde (Neurogenétics Department, Hospital Donostia, San Sebastián, Spain).